查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1585817

液态切片市场：按生物标记、最终用户划分 - 2025-2030 年全球预测

Breast Cancer Liquid Biopsy Market by Biomarker (Cell-free DNA, Circulating Tumor Cells, Extracellular Vesicles), End-User (Hospitals & Physician Laboratories, Reference Laboratories) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年液态切片市场价值为4.9429亿美元，预计到2024年将达到5.8992亿美元，复合年增长率为19.44%，到2030年将达到17.1415亿美元。

乳癌液态切片市场是一个快速发展的行业，专注于微创测试，能够实现癌症的早期检测、监测和个人化治疗。该技术透过分析患者血液中的循环肿瘤 DNA (ctDNA)，提供对肿瘤动态的全面了解。推动液态切片需求的主要因素包括全球乳癌盛行率的增加以及传统切片检查的局限性，例如侵入性和潜在的併发症。液态切片的应用范围从早期检测到监测治疗效果和识别潜在的復发。最终使用领域主要包括医院、诊断实验室和研究机构。

主要市场统计
基准年[2023] 4.9429 亿美元
预测年份 [2024] 5.8992 亿美元
预测年份 [2030] 1,714.15 百万美元
复合年增长率（%） 19.44%

市场成长受到基因组学和精准医学技术进步、人们对早期癌症检测益处的认识不断提高以及向非侵入性诊断技术的转变的影响。潜在的成长机会存在于新兴市场，这些市场不断增长的医疗保健支出和不断提高的意识正在放大成长前景。此外，生物技术公司和研究机构之间的合作有可能加速创新并改善获得这些先进诊断的机会。然而，挑战仍然存在，包括高成本、监管障碍以及与传统切片检查相比灵敏度有限，这可能会限制市场扩张。

最佳创新领域包括提高液体生物标记检测技术的灵敏度和特异性，以及整合人工智慧以增强液态切片资料的预测分析和解释。专注于多种癌症的早期检测和寻找新型生物标记的研究可以提供竞争优势。市场高度动态且分散，来自老牌公司和新兴企业的竞争非常激烈，因此公司投资研发和策略联盟非常重要。公司应专注于优化成本结构和简化监管途径，以提高采用率。在一个以快速技术创新和复杂法规为特征的市场中，策略规划的敏捷性和远见对于保持竞争优势和推动成长至关重要。

市场动态：快速发展的液态切片市场的关键市场洞察

供需的动态交互作用正在改变液态切片市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 全球乳癌发生率上升
    • 对非侵入性乳癌治疗的需求不断增加
    • 液态切片研究和开发的潜在资金
  • 市场限制因素
    • 液态切片高成本
  • 市场机会
    • 液态切片早期检测技术进展
    • 液态切片试剂核准增加
  • 市场挑战
    • 严格的监管问题和报销政策不足

波特五力：开拓液态切片市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解液态切片市场的外部影响

外部宏观环境因素在塑造液态切片市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解液态切片市场的竞争格局

液态切片市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵乳癌液态切片市场供应商的绩效评估

FPNV 定位矩阵是评估液态切片市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘了液态切片市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对乳癌液态切片市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监管核准、专利趋势、主要企业的技术进步等。

5.产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 全球乳癌发生率正在上升
      • 对非侵入性乳癌治疗的需求增加
      • 液态生物检体研究和开发的资金可用性
    • 抑制因素
      • 液态切片的费用很高。
    • 机会
      • 液态切片早期检测技术进展
      • 液态切片试剂核准增加
    • 任务
      • 严重的监管问题和糟糕的报销政策
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章液态切片市场生物标记

  • 游离DNA
  • 循环性肿瘤细胞
  • 细胞外囊泡

第七章液态切片市场：依最终用户分类

  • 医院和医生检查室
  • 参考实验室

第八章美洲液态切片市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第九章亚太液态切片市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十章欧洲、中东和非洲液态切片市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十一章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Adaptive Biotechnologies Corporation
  • Bio-Rad Laboratories, Inc.
  • Biocept, Inc.
  • Biodesix, Inc.
  • Epic Sciences Inc.
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd.
  • Fluxion Biosciences Inc.
  • Guardant Health, Inc.
  • Illumina, Inc.
  • Johnson & Johnson Services, Inc.
  • NeoGenomics Laboratories, Inc.
  • Qiagen NV by Thermo Fisher Scientific Inc.
  • Sysmex Corporation
  • The Menarini Group
Product Code: MRR-437D45958552

The Breast Cancer Liquid Biopsy Market was valued at USD 494.29 million in 2023, expected to reach USD 589.92 million in 2024, and is projected to grow at a CAGR of 19.44%, to USD 1,714.15 million by 2030.

The breast cancer liquid biopsy market is a rapidly evolving sector focused on minimally invasive tests enabling early cancer detection, monitoring, and personalized treatment. This method involves analyzing circulating tumor DNA (ctDNA) in a patient's blood, offering a comprehensive view of tumor dynamics. Key factors driving its necessity include the increasing global prevalence of breast cancer and the limitations of traditional biopsies, such as invasiveness and potential complications. Applications of liquid biopsy span from early detection to monitoring treatment efficacy and identifying potential relapse, thus enhancing precision and personalization in patient care. End-use segments primarily include hospitals, diagnostic laboratories, and research institutes.

KEY MARKET STATISTICS
Base Year [2023] USD 494.29 million
Estimated Year [2024] USD 589.92 million
Forecast Year [2030] USD 1,714.15 million
CAGR (%) 19.44%

Market growth is influenced by technological advancements in genomics and precision medicine, increasing awareness of early cancer detection benefits, and a shift towards non-invasive diagnostic techniques. Potential opportunities lie in emerging markets, where increasing healthcare expenditure and heightened awareness amplify growth prospects. Additionally, partnerships between biotech firms and research institutions could accelerate innovation and improve accessibility to these advanced diagnostics. However, challenges remain in the form of high costs, regulatory hurdles, and limited sensitivity compared to traditional tissue biopsies, potentially restraining market expansion.

The best areas for innovation include improving the sensitivity and specificity of liquid biomarker detection techniques and integrating artificial intelligence to enhance predictive analytics and interpretation of liquid biopsy data. Research focused on multi-cancer early detection and the exploration of new biomarkers could provide competitive advantages. The market is highly dynamic and fragmented with strong competition among established players and rising startups, making it crucial for companies to invest in R&D and strategic collaborations. Businesses should focus on optimizing cost structures and simplifying regulatory pathways to enhance adoption rates. In a market characterized by rapid technological updates and regulatory complexities, agility and foresight in strategic planning are vital for sustaining competitive advantage and fostering growth.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Breast Cancer Liquid Biopsy Market

The Breast Cancer Liquid Biopsy Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of breast cancer worldwide
    • Increasing demand for non-invasive breast cancer treatment
    • Availability of funding for liquid biopsy R&D
  • Market Restraints
    • High cost of breast cancer liquid biopsy
  • Market Opportunities
    • Technological advancements in early-stage detection of breast cancer liquid biopsy
    • Increasing breast cancer liquid biopsy reagent approvals
  • Market Challenges
    • Stringent regulatory issues and poor reimbursement policies

Porter's Five Forces: A Strategic Tool for Navigating the Breast Cancer Liquid Biopsy Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Breast Cancer Liquid Biopsy Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Breast Cancer Liquid Biopsy Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Breast Cancer Liquid Biopsy Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Breast Cancer Liquid Biopsy Market

A detailed market share analysis in the Breast Cancer Liquid Biopsy Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Breast Cancer Liquid Biopsy Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Breast Cancer Liquid Biopsy Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Breast Cancer Liquid Biopsy Market

A strategic analysis of the Breast Cancer Liquid Biopsy Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Breast Cancer Liquid Biopsy Market, highlighting leading vendors and their innovative profiles. These include Adaptive Biotechnologies Corporation, Bio-Rad Laboratories, Inc., Biocept, Inc., Biodesix, Inc., Epic Sciences Inc., Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., Fluxion Biosciences Inc., Guardant Health, Inc., Illumina, Inc., Johnson & Johnson Services, Inc., NeoGenomics Laboratories, Inc., Qiagen N. V. by Thermo Fisher Scientific Inc., Sysmex Corporation, and The Menarini Group.

Market Segmentation & Coverage

This research report categorizes the Breast Cancer Liquid Biopsy Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Biomarker, market is studied across Cell-free DNA, Circulating Tumor Cells, and Extracellular Vesicles.
  • Based on End-User, market is studied across Hospitals & Physician Laboratories and Reference Laboratories.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of breast cancer worldwide
      • 5.1.1.2. Increasing demand for non-invasive breast cancer treatment
      • 5.1.1.3. Availability of funding for liquid biopsy R&D
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of breast cancer liquid biopsy
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological advancements in early-stage detection of breast cancer liquid biopsy
      • 5.1.3.2. Increasing breast cancer liquid biopsy reagent approvals
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory issues and poor reimbursement policies
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Breast Cancer Liquid Biopsy Market, by Biomarker

  • 6.1. Introduction
  • 6.2. Cell-free DNA
  • 6.3. Circulating Tumor Cells
  • 6.4. Extracellular Vesicles

7. Breast Cancer Liquid Biopsy Market, by End-User

  • 7.1. Introduction
  • 7.2. Hospitals & Physician Laboratories
  • 7.3. Reference Laboratories

8. Americas Breast Cancer Liquid Biopsy Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Breast Cancer Liquid Biopsy Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Breast Cancer Liquid Biopsy Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Adaptive Biotechnologies Corporation
  • 2. Bio-Rad Laboratories, Inc.
  • 3. Biocept, Inc.
  • 4. Biodesix, Inc.
  • 5. Epic Sciences Inc.
  • 6. Exact Sciences Corporation
  • 7. F. Hoffmann-La Roche Ltd.
  • 8. Fluxion Biosciences Inc.
  • 9. Guardant Health, Inc.
  • 10. Illumina, Inc.
  • 11. Johnson & Johnson Services, Inc.
  • 12. NeoGenomics Laboratories, Inc.
  • 13. Qiagen N. V. by Thermo Fisher Scientific Inc.
  • 14. Sysmex Corporation
  • 15. The Menarini Group

LIST OF FIGURES

  • FIGURE 1. BREAST CANCER LIQUID BIOPSY MARKET RESEARCH PROCESS
  • FIGURE 2. BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. BREAST CANCER LIQUID BIOPSY MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. BREAST CANCER LIQUID BIOPSY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BREAST CANCER LIQUID BIOPSY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BREAST CANCER LIQUID BIOPSY MARKET DYNAMICS
  • TABLE 7. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CELL-FREE DNA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CIRCULATING TUMOR CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXTRACELLULAR VESICLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY HOSPITALS & PHYSICIAN LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 15. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 16. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 17. ARGENTINA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 18. ARGENTINA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 19. BRAZIL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 20. BRAZIL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 21. CANADA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 22. CANADA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 23. MEXICO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 24. MEXICO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 25. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 26. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 27. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 28. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 29. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 30. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 31. AUSTRALIA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 32. AUSTRALIA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 33. CHINA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 34. CHINA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 35. INDIA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 36. INDIA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 37. INDONESIA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 38. INDONESIA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 39. JAPAN BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 40. JAPAN BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 41. MALAYSIA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 42. MALAYSIA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 43. PHILIPPINES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 44. PHILIPPINES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 45. SINGAPORE BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 46. SINGAPORE BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 47. SOUTH KOREA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 48. SOUTH KOREA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 49. TAIWAN BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 50. TAIWAN BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 51. THAILAND BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 52. THAILAND BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 53. VIETNAM BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 54. VIETNAM BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 55. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 56. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 57. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 58. DENMARK BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 59. DENMARK BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 60. EGYPT BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 61. EGYPT BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 62. FINLAND BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 63. FINLAND BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 64. FRANCE BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 65. FRANCE BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 66. GERMANY BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 67. GERMANY BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 68. ISRAEL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 69. ISRAEL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 70. ITALY BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 71. ITALY BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 72. NETHERLANDS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 73. NETHERLANDS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 74. NIGERIA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 75. NIGERIA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 76. NORWAY BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 77. NORWAY BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 78. POLAND BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 79. POLAND BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 80. QATAR BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 81. QATAR BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 82. RUSSIA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 83. RUSSIA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 84. SAUDI ARABIA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 85. SAUDI ARABIA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 88. SPAIN BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 89. SPAIN BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 90. SWEDEN BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 91. SWEDEN BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 92. SWITZERLAND BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 93. SWITZERLAND BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 94. TURKEY BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 95. TURKEY BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 96. UNITED ARAB EMIRATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED ARAB EMIRATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED KINGDOM BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED KINGDOM BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 100. BREAST CANCER LIQUID BIOPSY MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 101. BREAST CANCER LIQUID BIOPSY MARKET, FPNV POSITIONING MATRIX, 2023